Aura Biosciences (AURA): Cheap Optionality on a Clinical Pipeline with Cash Support
Aura Biosciences is a clinical-stage oncology company trading near $6.84 with a market cap around $707M and roughly $5.08 in reported cash per share. Recent financing and management moves reduce near-term dilution risk and set up asymmetric upside if belzupacap sarotalocan (AU-011) posts positive data. This trade idea lays out an entry, stop and tw…